PAB
PATRYS FPO [PAB]
· ASX Small Cap
$0.0320 +0.0%
Updated 9 Sep 2026 · Signals refresh every scan
Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when PAB triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD momentum is picking up steam
- Volume surging at 6.4x normal while price falls — heavy selling pressure
- Watch out — volume is flowing out even as price holds up. Distribution pattern
- Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
- Adequate cash runway (6 quarters)
- 4C filed 2026-07-21
- Very high P/S ratio (1248.2x)
- Revenue in sharp decline (-93%)
- Micro-cap ($5-20M) - high risk
- Capital raise activity (1 events)
- Sentiment is mixed — no strong consensus either way
- Altman Z-Score distress zone (1.52 < 1.81, low-confidence approx)
- Low-priced stock risk ($0.032)
- RBA hiking (-3pts)
Risk Signals
- Piotroski F-Score weak (3/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
- Revenue declining at -93% — the top line is shrinking
- The bigger volume days are the down days — volume-weighted momentum is negative (-2.49%/day)
Expected next for PAB
Window: 15 Oct to 29 Oct
The last 9 moved PAB -2.4% on the day, on average — an observation, not a guide to what happens next.
Window: 26 Oct to 9 Nov
The last 9 moved PAB -2.4% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →
Recent Catalysts
NONE Appendix 4E - Preliminary Final Report
NONE Cleansing Notice
MEDIUM Ethics Approval Secured for Phase 1A Clinical Trial
LOW Investor Presentation - TechKnow Invest Roadshow
LOW Appendix 4C - Quarterly - 30 June 2026
Announcement tone +3pts
Recent ASX Announcements
| 2026-08-31 | Appendix 4E - Preliminary Final Report PRICE SENSITIVE |
| 2026-08-27 | Ethics Approval Secured for Phase 1A Clinical Trial PRICE SENSITIVE |
| 2026-07-26 | Investor Presentation - TechKnow Invest Roadshow PRICE SENSITIVE |
| 2026-07-21 | Appendix 4C - Quarterly - 30 June 2026 PRICE SENSITIVE |
| 2026-07-15 | Cleansing Notice |
Key Metrics
$11.2M
Market Cap
270K
Avg Volume
6.4x
Vol Ratio
$0.03 — $0.05
52-Week Range
N/A
Short Interest
6 qtrs
Cash Runway
-62.6%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 138% |
| L | Leader vs Laggard | laggard | RS: -20 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Track PAB and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required